Talimogene laherparepvec (T-VEC), the first clinically approved OV, is a genetically modified oHSV expressing granulocyte-macrophage colony-stimulating factor (GM-CSF), which is used for melanoma treatment (7). Here, CSF2 is linked to melanoma.